Sanofi turns to G-BA for Jevtana benefits decision after vague IQWiG's assessment
This article was originally published in Scrip
Executive Summary
Sanofi'sJevtana (cabazitaxel) could offer considerable additional benefit for castration-resistant prostate cancer patients aged 65 and over who are unable to continue with docetaxel (Sanofi's Taxotere), says IQWiG, the German HTA institute. Meanwhile, for patients under 65 there is just a "hint" of unquantifiable benefit. The assessment is vague and leaves too much scope for interpretation, says EUCOPE, the European Confederation of Pharmaceutical Entrepreneurs.
You may also be interested in...
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.
New HTA Evidence Guidelines In EU Could Spell Trouble For Advanced Therapy Companies
New guidelines that cast doubt over the use of single-arm and non-randomized studies are “discouraging” for rare disease patients and the advanced therapy sector, says ARM, the Alliance for Regenerative Medicines.